title: Selection of optimal drug therapy for the patient with angina pectoris.
abstract: The development of new drugs, especially beta-blocking and calcium entry-blocking agents, has greatly facilitated the medical treatment of angina pectoris. The specific needs of each patient should dictate the appropriate treatment of angina pectoris. Angina may occur in patients who have various concomitant disorders such as hypertension, diabetes mellitus, peripheral vascular disease, chronic obstructive pulmonary disease, or arrhythmias, and the physician must take these factors into account when a drug regimen is prescribed. Individual drugs should be chosen on the basis of specifically desired pharmacologic effects, and the dosages should be gradually adjusted according to the patient's response. Although a therapeutic regimen should be selected primarily on the basis of efficacy, the physician must also attempt to recommend a simple and cost-effective program.
authors.forename: C
authors.initials: C
authors.lastname: Shub
authors.forename: R E
authors.initials: RE
authors.lastname: Vlietstra
authors.forename: M D
authors.initials: MD
authors.lastname: McGoon
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D000787:Angina Pectoris / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D001145:Arrhythmias, Cardiac / Q000150:complications; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D003922:Diabetes Mellitus, Type 1 / Q000150:complications; D004110:Diltiazem / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004361:Drug Tolerance; D006339:Heart Rate / Q000187:drug effects; D006352:Heart Ventricles / Q000503:physiopathology; D006801:Humans; D006973:Hypertension / Q000150:complications; D007674:Kidney Diseases / Q000150:complications; D008171:Lung Diseases / Q000150:complications; D009206:Myocardium / Q000378:metabolism; D009543:Nifedipine / Q000627:therapeutic use; D009566:Nitrates / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D005082:Physical Exertion; D011943:Receptors, Adrenergic, beta / Q000502:physiology; D013599:Systole; D014652:Vascular Diseases / Q000150:complications; D014664:Vasodilation / Q000187:drug effects; D014700:Verapamil / Q000627:therapeutic use
chemical_list: D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D009566:Nitrates; D011943:Receptors, Adrenergic, beta; D014700:Verapamil; D004110:Diltiazem; D009543:Nifedipine